Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory and data firm focused on the developing cannabis and hemp markets, is pleased to announce its support of Congress’s Farm Bill, which legalizes the production and sale of hemp.
LAS VEGAS, /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory and data firm focused on the developing cannabis and hemp markets, is pleased to announce its support of Congress's Farm Bill, which legalizes the production and sale of hemp. The Farm Bill is expected to be signed by the President shortly, and will then take immediate effect. As one of Nevada's first licensed cannabis testing laboratories, Digipath has extensive experience testing hemp over the past two years. It is anticipated that following the effectiveness of the Farm Bill, demand for both hemp and the testing of hemp will grow significantly. In fact, Fortune magazine, in a recent post reacting to the Senate's passage of the Farm Bill, predicted that the U.S. cannabis industry could grow to $20 billion by 2022 from $800 million this year. "Passage of The Farm Bill could be enormously beneficial to our expansion efforts," stated Todd Denkin, CEO and Founder, Digipath, Inc. "Federal legalization is expected to expand our addressable market, and we intend to aggressively pursue a Digipath presence in viable new markets that emerge. With the advent of hemp legalization, it is not just raw hemp that will require testing. Rather, all products containing hemp and hemp byproducts that are already starting to infiltrate our grocery and drug store shelves, such as cosmetics, creams, tinctures, and patches will all need to be tested before they reach consumers. Digipath is able to provide that testing." About Digipath, Inc. & Digipath Labs, Inc. Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization. Digipath Investor Relations & Financial Media info@integrityir.com Information about Forward-Looking Statements
SOURCE Digipath, Inc. |
||
Company Codes: OTC-QB:DIGP, OTC-PINK:DIGP |